DV Biomed (Taiwan) Performance
| 6539 Stock | TWD 66.60 0.20 0.30% |
The firm owns a Beta (Systematic Risk) of -0.0265, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning DV Biomed are expected to decrease at a much lower rate. During the bear market, DV Biomed is likely to outperform the market. At this point, DV Biomed has a negative expected return of -0.12%. Please make sure to confirm DV Biomed's market risk adjusted performance, coefficient of variation, jensen alpha, as well as the relationship between the mean deviation and standard deviation , to decide if DV Biomed performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days DV Biomed Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Quick Ratio | 1.97 | |
| Fifty Two Week Low | 35.31 | |
| Payout Ratio | 32.47% | |
| Fifty Two Week High | 75.50 | |
| Trailing Annual Dividend Yield | 2.40% |
6539 |
DV Biomed Relative Risk vs. Return Landscape
If you would invest 7,230 in DV Biomed Co on September 1, 2024 and sell it today you would lose (570.00) from holding DV Biomed Co or give up 7.88% of portfolio value over 90 days. DV Biomed Co is generating negative expected returns and assumes 1.0089% volatility on return distribution over the 90 days horizon. Simply put, 8% of stocks are less volatile than 6539, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
DV Biomed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for DV Biomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as DV Biomed Co, and traders can use it to determine the average amount a DV Biomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1222
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6539 |
Estimated Market Risk
| 1.01 actual daily | 8 92% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average DV Biomed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of DV Biomed by adding DV Biomed to a well-diversified portfolio.
DV Biomed Fundamentals Growth
6539 Stock prices reflect investors' perceptions of the future prospects and financial health of DV Biomed, and DV Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 6539 Stock performance.
| Return On Equity | 23.52 | |||
| Return On Asset | 8.85 | |||
| Profit Margin | 16.64 % | |||
| Operating Margin | 14.88 % | |||
| Current Valuation | 3.68 B | |||
| Shares Outstanding | 59.26 M | |||
| Price To Earning | 13.49 X | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 2.22 X | |||
| Revenue | 1.81 B | |||
| EBITDA | 448.99 M | |||
| Cash And Equivalents | 538.29 M | |||
| Cash Per Share | 9.14 X | |||
| Total Debt | 249.93 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | 20.43 X | |||
| Cash Flow From Operations | 463.36 M | |||
| Earnings Per Share | 5.04 X | |||
About DV Biomed Performance
Evaluating DV Biomed's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if DV Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DV Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and internationally. The company was founded in 2011 and is based in Taipei, Taiwan. UnicoCell operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about DV Biomed performance evaluation
Checking the ongoing alerts about DV Biomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DV Biomed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DV Biomed generated a negative expected return over the last 90 days |
- Analyzing DV Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DV Biomed's stock is overvalued or undervalued compared to its peers.
- Examining DV Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DV Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of DV Biomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DV Biomed's stock. These opinions can provide insight into DV Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for 6539 Stock Analysis
When running DV Biomed's price analysis, check to measure DV Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DV Biomed is operating at the current time. Most of DV Biomed's value examination focuses on studying past and present price action to predict the probability of DV Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DV Biomed's price. Additionally, you may evaluate how the addition of DV Biomed to your portfolios can decrease your overall portfolio volatility.